Circulating osteopontin as a marker of early coronary vascular calcification in type two diabetes mellitus patients with known asymptomatic coronary artery disease

Berezin, Alexander E.; Kremzer, Alexander A.

doi:10.1016/j.atherosclerosis.2013.06.003

Cited by 67 publications

(52 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our findings are in line with data from type 2 diabetic patients in which elevated circulating OPN levels were associated with the presence and development of coronary artery disease and artery calcification (14,15). Several studies described OPN as a key regulator of adipose tissue inflammation and IR; notably, both serum levels and adipose tissue expression of the number of pro-inflammatory cytokines, such as IL6, TNFa, MCP-1 and iNOS, were significantly reduced in experimental models of mice lacking the OPN gene (11).…”

Section: Discussionsupporting

confidence: 82%

See 1 more Smart Citation

Increased circulating osteopontin levels in adult patients with type 1 diabetes mellitus and association with dysmetabolic profile

Barchetta¹,

Alessandri

Bertoccini³

et al. 2016

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Osteopontin (OPN) is a sialoprotein implicated in different immunity and metabolic pathways. Capable of activating dendritic cells and inducing Th1-Th17-mediated tissue damage, OPN plays a significant role in the development/progression of several autoimmune diseases; interestingly, it was also shown that OPN participates in the acute pancreatic islets response to experimentally induced diabetes in non-obese diabetic (NOD) mice. Furthermore, OPN promotes adipose tissue dysfunction, systemic inflammation and insulin resistance. Our aims of this study were to evaluate circulating OPN levels in adult patients with type 1 diabetes mellitus (T1DM) compared to non-diabetic control participants and to unravel clinical and biochemical correlates of OPN concentration. Design: Case-control study. Methods: We enrolled 54 consecutive T1DM patients referred to our diabetes outpatient clinic at Sapienza University of Rome and 52 healthy sex and age-comparable controls. The study population underwent clinical evaluation, blood sampling for biochemistry and complete screening for diabetes complications. Serum OPN levels were measured by MILLIPLEX Multiplex Assays Luminex. Results: T1DM patients had significantly higher serum OPN levels than controls (17.2G12.9 vs 10.5G11.6 mg/ml, PZ0.009). OPN levels correlated with T1DM, higher blood pressure, BMI, creatinine, g-GT, ALP and lower HDL; the association between high OPN levels and T1DM was independent from all confounders. No correlation was shown between OPN and HbA1c, C-peptide, insulin requirement, co-medications and diabetes duration. Conclusions: This study demonstrates for the first time in a case-control study that adults with T1DM have increased serum OPN levels, and that higher OPN concentrations are associated with an unfavorable metabolic profile in these patients.

show abstract

Section: Discussionsupporting

confidence: 82%

“…Increased OPN levels were found in obese participants (12,13) and predicted coronary calcification, nephropathy and coronary artery disease in patients with type 2 diabetes, independent of traditional risk factors (14,15).…”

Section: Introductionmentioning

confidence: 99%

Increased circulating osteopontin levels in adult patients with type 1 diabetes mellitus and association with dysmetabolic profile

Barchetta¹,

Alessandri

Bertoccini³

et al. 2016

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…In addition to established risk factors, several biomarkers associated with atherosclerosis, inflammation and congestive heart failure [6][7][8][9][10][11] have recently been proposed to improve risk stratification in type 2 diabetes mellitus patients. Promising data have been obtained using biomarkers associated with the closely interlinked processes of atherosclerosis and low-grade systemic inflammation [12].…”

Section: Introductionmentioning

confidence: 99%

ANGPTL2 is associated with an increased risk of cardiovascular events and death in diabetic patients

et al. 2016

View full text Add to dashboard Cite

Aims/hypothesis A high serum angiopoietin-like 2 (ANGPTL2) concentration is an independent risk factor for developing diabetes and is associated with insulin resistance and atherosclerosis. In this work, we have examined the impact of serum ANGPTL2 on improving cardiovascular (CV) risk stratification in patients with type 2 diabetes.Methods A prospective, monocentric cohort of consecutive type 2 diabetes patients (the SURDIAGENE cohort; total of 1353 type 2 diabetes patients; 58% men, mean ± SD age 64 ± 11 years) was followed for a median of 6.0 years for death as primary endpoint and major adverse CV events (MACE; i.e. CV death, myocardial infarction or stroke) as a secondary endpoint. Patients with end-stage renal disease, defined as a requirement for dialysis or a history of kidney transplantation, Eric Thorin and Samy Hadjadj contributed equally to this study. Electronic supplementary material

show abstract

“…Although OPN, OPG, and RANKL/RANK components are well-known biomarkers of vascular calcification, systemic inflammation, atherosclerosis, kidney dysfunction, and cardiac remodeling, their predictive role in HF is still uncertain (Berezin and Kremzer, 2013a;. There is evidence regarding that the sRANKL/OPG complex may relate to HFrEF development, whereas circulating levels of OPN and OPG corresponded to HFpEF (Berezin and Kremzer, 2014a, c).…”

Section: Bone-related Proteinsmentioning

confidence: 99%

Up-to-date clinical approaches of biomarkers’ use in heart failure

Berezin¹

2017

Biomed. Res. Ther.

View full text Add to dashboard Cite

Heart failure (HF) is considered a leading cause of death in patients with established cardiovascular (CV) and metabolic diseases. Although current treatment strategy has improved survival rate and clinical outcomes of HF, the HF prevalence exhibits growth especially in older patients' population and survivors after coronary atherothrombotic events. Current clinical guidelines regarding treatment and prevention of HF claim the role of biological markers as pretty easy and powerful tool for diagnosis, risk stratification, and prognostication of HF. However, there is not clear whether all these biological markers are able to equally predict CV death and HF-related outcomes in patients with acute and chronic HF as well as in various phenotypes of HF. The aim of the review is to discuss a role of in risk stratification and individual treatment in patients with different phenotypes of HF.

show abstract

Circulating osteopontin as a marker of early coronary vascular calcification in type two diabetes mellitus patients with known asymptomatic coronary artery disease

Cited by 67 publications

References 31 publications

Increased circulating osteopontin levels in adult patients with type 1 diabetes mellitus and association with dysmetabolic profile

Increased circulating osteopontin levels in adult patients with type 1 diabetes mellitus and association with dysmetabolic profile

ANGPTL2 is associated with an increased risk of cardiovascular events and death in diabetic patients

Up-to-date clinical approaches of biomarkers’ use in heart failure

Contact Info

Product

Resources

About